TABLE 2.
Commonly used targeting ligands and targeting receptor for targeted cancer nanomedicine.
| Name of the nanocarriers | Targeting ligands (small molecules, peptides, aptamers, proteins, antibodies) | Targeting receptor | Name of the cell line used | Types of cancer |
|---|---|---|---|---|
| Cis-diamine platinum drug and siRNA-loaded dendrimer-based nanoparticles | Folic acid | Folate receptor-α | H1299 - Lung cancer cells | Lung cancer Amreddy et al. (2018) |
| Gum kondagogu capped gold nanoparticles | Folic acid | Folate receptor | MCF-7 - Breast cancer cells | Breast cancer Kumar et al. (2018) |
| Doxorubicin-loaded pullulan-based nanocarriers | Arabinogalactan (a galactose-based polymer) and pullulan (a glucose-based polymer) | Asialoglycoprotein receptor (ASGPR) | HepG2 - Human hepatocellular carcinoma cells | Liver cancer (Pranatharthiharan et al., 2017) |
| Curcumin and doxorubicin-loaded hyaluronic acid-based nanoparticles | Hyaluronic acid | CD 44 receptor | A549 - Human non-small lung cancer cells; HepG2 - Human hepatocellular carcinoma cells | Lung and Liver cancer Diao et al. (2019) |
| Docetaxel loaded Trastuzumab-Coated Nanoparticles | Trastuzumab (Herceptin) | Human epidermal growth factor receptor 2 (HER2) | BT474—Breast cancer cells | Breast cancer Zhang et al. (2019) |
| Doxorubicin loaded liposomal-based nanocarrier | Human anti-CD20 monoclonal antibody | B-lymphocytes | CD20-positive Raji cells derived from Burkitt’s lymphoma | B cell lymphoma (Jiang et al., 2016) |
| Doxorubicin encapsulated polymeric nanoparticles | Biotinylated mouse anti-human CD19Ab | CD 19 receptor | RS4; 11 and REH cells - Human acute leukemia cell lines | Acute Lymphoblastic Leukemia (ALL) Krishnan et al. (2015) |
| Doxorubicin-loaded silver-coated gold nanorods | Epithelial cell adhesion/activating molecule | Epithelial cell adhesion/activating molecule (EpCAM receptor; CD326) | 4T1—Breast cancer cells | Breast cancer (Jenkins et al., 2017) |
| Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles | Cetuximab | EGFR receptor | U-87MG - a human glioma cell lines | Glioblastomas Duwa et al. (2020) |
| Doxorubicin loaded bevacizumab modified nanoparticles | Bevacizumab antibody | VEGF receptor | SH-SY5Y - Human neuroblastoma cell line | Neuroblastoma Zhu et al. (2017) |
| Gold nanoparticles | Transferring peptide (Tfpep) | Transferrin receptor | U87 - Human glioma cells; LN229—glioblastoma cells | Brain tumors Dixit et al. (2015) |
| Iron Oxide nanoparticles | LHRH-R peptide and uPAR peptide | Luteinizing hormone-releasing hormone receptor [LHRH-R] and Urokinase-type plasminogen activator receptor [uPAR] | PC-3—Human prostate carcinoma cells | Prostate cancer (Ahmed et al., 2017) |
| Solid lipid nanoparticles | cyclic arginyl-glycyl-aspartic acid (cRGD) peptides | αvβ3 integrin receptor | MDA-MB-231 - human triple-negative breast cancer cell line | Breast cancer Shan et al. (2015) |